$RLYB News

Rallybio Q3 EPS $(0.48) Misses $(0.21) Estimate

Rallybio Declares $82.7M Special Cash Distribution To Stockholders And Pre-Funded Warrant Holders, Estimated At $13.56/Share, In Connection With Avenzo Therapeutics Merger

Rallybio Announces CFO Jonathan Lieber To Transition To Part-Time Employment Effective September 15, Remaining CFO And Principal Financial Officer; Employment To Terminate Upon Closing Of Avenzo Therapeutics Business Combination

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?

RallyBio tries again for reverse merger, this time with Avenzo

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

Rallybio To Acquire Avenzo Therapeutics; Avenzo Entered Into $215M Private Placement Financing

RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters

Rallybio to acquire Candid Therapeutics

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Rallybio shares are trading higher after the company agreed to a merger deal with Candid Therapeutics.

Rallybio shares are trading higher after the company agreed to a merger deal with Candid Therapeutics.

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

Candid, in a reverse merger with RallyBio, to go public

Rallybio Corporation Shares Resume Trade

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Rallybio To Acquire Candid Therapeutics Under All-Stock Merger Agreement

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending